RecallHawk

DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE (DEXTROAMPHET...

TAKEDA PHARMS USA

Summary

FDA approved DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE (DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE) by TAKEDA PHARMS USA. NDA (New Drug) approval (Labeling) on 2026-04-23. CAPSULE, EXTENDED RELEASE, ORAL.

Details

Source

Drug Approval

External ID

NDA021303-40

Action Date

2026-04-23

Status

Approved

Category

drug

Product Code

NDA (New Drug)

Product Description

DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE (generic: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE), CAPSULE, EXTENDED RELEASE, ORAL. Application: NDA021303

Context & Analysis

TAKEDA PHARMS USA has 13 FDA actions in our database.

Frequently Asked Questions

How often does TAKEDA PHARMS USA have FDA actions?

TAKEDA PHARMS USA has 13 FDA actions in our database, including 0 recalls and 0 device clearances.

Where can I find the official FDA record?

The official record is available on FDA.gov. Search for "NDA021303-40" on FDA.gov for the full record. You can also use the openFDA API to query this record programmatically.

Want to know the moment something like this happens?

Get alerts for drug

Related Actions